Podcasts
Latest Podcast
25 November 2020
Metabolic
Speaker: Assoc Prof Dr David Sim
SC-MY-00960
SGLT2 inhibitors and Heart Failure: What's New?
Our host speaks with Assoc Prof Dr David Sim, Consultant Cardiologist and President of the Heart Failure Society Singapore (HFSS) and the Director of the Heart Failure Programme at National Heart Centre Singapore, to discuss the clinical findings from the EMPEROR-Reduced trial, the role of SGLT2 inhibitors in heart failure treatment and the updates to the recently published Heart Failure Guidelines by the HFSS.Note: Empagliflozin is not indicated for the treatment of heart failure with reduced ejection fraction.
22 July 2020
Metabolic
Speaker: Dr Aslannif Roslan
SC-MY-00769
EMPA-HEART study: Mechanistic Insight of Empagliflozin Mediated Cardiac Benefits
Our host speaks with Dr Aslannif, Cardiologist at National Heart Institute Malaysia and the former chairperson of Society of Cardiac Imaging Malaysia (SCIM) to discuss on the clinical findings from EMPA-HEART CardioLink-6 study. ×
References:
1.
Verma S. et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation August 2019; 140 (21): 1693–1702
2.
Luca N. et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: The REASON echocardiography study. American Journal of Hypertension. August 2004; 17 (8): 660-667
3.
Abdi-Ali A et al. LV Mass Independently Predicts Mortality and Need for Future Revascularization in Patients Undergoing Diagnostic Coronary Angiography. JACC Cardiovasc Imaging March 2018;11 (3) :423-433
23 June 2020
Cardiovascular
Speaker: Dr. Gary Lee
SC-MY-00724
Managing Atrial Fibrillation in Elderly Patients.
Atrial Fibrillation is one of the most common diseases in aging population. In this podcast, Dr. Gary Lee, a Consultant Cardiologist & Electrophysiologist will be sharing his experience on what are the important managements in this group of patients.
15 June 2020
Metabolic
Speaker: Dr Gerard Leong, Dr Saiful Bahari Kassim
SC-MY-00720
Why Metabolic Syndrome Matters in Diabetes and Heart Failure
Our host speaks with Dr Saiful Bahari Kassim, Consultant Endocrinologist from Gleneagles Hospital KL and Dr Gerard Leong, Specialist in Cardiology practising at Gerard Leong Cardiology Clinic, Thomson Medical Centre Singapore, to discuss about why metabolic syndrome matters in diabetes and heart failure. They also discuss about the management of diabetic patients with heart failure in the context of metabolic syndrome.
21 May 2020
Metabolic
Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen
SC-MY-00694
Who SAID we can't ACE prescribing in the setting of COVID-19? – Part I
Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19.In part I of the episode, they discuss about the controversy surrounding the use of non-steroidal anti-inflammatory drugs (NSAIDs) and angiotensin-converting enzyme (ACE) inhibitors during the coronavirus pandemic, as well as the risk of patients with hypertension and diabetes in the context of COVID-19.×
References:
1.
Fang L, et al. Lancet 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? (Source)
2.
Pharmaceutical Society of Singapore. COVID-19 Advice for the General Public. (Source)
3.
WHO. Coronavirus disease (COVID-19) advice for the public: Myth-busters. (Source)
4.
ESC Guidance for the Diagnosis and Management of CV disease during the COVID-19 Pandemic. April 2020. (Source)
5.
Singapore Cardiac Society, Heart Failure Society (Singapore) and Academy of Medicine Singapore – Chapter of Cardiology Joint Position Statement on COVID-19 and use of ARB/ACEi. (Source)
21 May 2020
Metabolic
Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen
SC-MY-00695
Who SAID we can't ACE prescribing in the setting of COVID-19? – Part II
Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19.In part II of the episode, they discuss about the current evidence available on the potential therapies for COVID-19. They also discuss about considerations surrounding the use of these agents in COVID-19 patients during hospitalization and post-discharged.
×
References:
1.
FDA. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. (Source)
2.
Sanders JM, et al. JAMA 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (Source)
3.
Guidicessi JR, et al. Mayo Clin Proc 2020. Guidance for navigating QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. (Source)
21 May 2020
Metabolic
Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen
SC-MY-00696
Who SAID we can't ACE prescribing in the setting of COVID-19? – Part III
Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19.In part III of the episode, they discuss about the safety of statins during the COVID-19 pandemic and our guests share their most important takeaways on the use of medications in the setting of COVID-19.
×
References:
1.
Sanders JM, et al. JAMA 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (Source)
2.
ESC Guidance for the Diagnosis and Management of CV disease during the COVID-19 Pandemic. April 2020. (Source)
3.
WHO. Coronavirus disease (COVID-19) advice for the public: Myth-busters. (Source)
4.
Guidicessi JR, et al. Mayo Clin Proc 2020. Guidance for navigating QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. (Source)
27 April 2020
Metabolic
Speaker: Professor Dr.Rohana Abdul Ghani
PC-MY-100949
Fast Tips on Management of Diabetes During Ramadan
Our host today, Head of Medical at Boehringer Ingelheim, Dr Azhar, will be talking with Prof. Dr Rohana, the consultant endocrinologist and deputy dean at the faculty of Medicine, Universiti Teknologi MARA, to share with us some Fast Tips on the management of diabetes during Ramadan. Prof Rohana will also share what options the healthcare providers and the patients have available to optimize diabetes care during this COVID19
17 April 2020
Cardiovascular
Speaker: Prof. Dr. Chee Kok Han
SC-MY-00636
Managing Anticoagulation in Atrial Fibrillation during the COVID-19 Pandemic
The corona virus has brought changes to the way patients are being managed. Does this situation also affect the way Atrial Fibrillation patients are managed? Find out in this podcast where Prof. Dr. Chee Kok Han, Senior Consultant Cardiologist and Professor at the University of Malaya shares on the management of anticoagulated atrial fibrillation patients amidst the coronavirus pandemic.
Metabolic
25 November 2020
Metabolic
Speaker: Assoc Prof Dr David Sim
SC-MY-00960
SGLT2 inhibitors and Heart Failure: What's New?
Our host speaks with Assoc Prof Dr David Sim, Consultant Cardiologist and President of the Heart Failure Society Singapore (HFSS) and the Director of the Heart Failure Programme at National Heart Centre Singapore, to discuss the clinical findings from the EMPEROR-Reduced trial, the role of SGLT2 inhibitors in heart failure treatment and the updates to the recently published Heart Failure Guidelines by the HFSS.Note: Empagliflozin is not indicated for the treatment of heart failure with reduced ejection fraction.
22 July 2020
Metabolic
Speaker: Dr Aslannif Roslan
SC-MY-00769
EMPA-HEART study: Mechanistic Insight of Empagliflozin Mediated Cardiac Benefits
Our host speaks with Dr Aslannif, Cardiologist at National Heart Institute Malaysia and the former chairperson of Society of Cardiac Imaging Malaysia (SCIM) to discuss on the clinical findings from EMPA-HEART CardioLink-6 study. ×
References:
1.
Verma S. et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation August 2019; 140 (21): 1693–1702
2.
Luca N. et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: The REASON echocardiography study. American Journal of Hypertension. August 2004; 17 (8): 660-667
3.
Abdi-Ali A et al. LV Mass Independently Predicts Mortality and Need for Future Revascularization in Patients Undergoing Diagnostic Coronary Angiography. JACC Cardiovasc Imaging March 2018;11 (3) :423-433
15 June 2020
Metabolic
Speaker: Dr Gerard Leong, Dr Saiful Bahari Kassim
SC-MY-00720
Why Metabolic Syndrome Matters in Diabetes and Heart Failure
Our host speaks with Dr Saiful Bahari Kassim, Consultant Endocrinologist from Gleneagles Hospital KL and Dr Gerard Leong, Specialist in Cardiology practising at Gerard Leong Cardiology Clinic, Thomson Medical Centre Singapore, to discuss about why metabolic syndrome matters in diabetes and heart failure. They also discuss about the management of diabetic patients with heart failure in the context of metabolic syndrome.21 May 2020
Metabolic
Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen
SC-MY-00694
Who SAID we can't ACE prescribing in the setting of COVID-19? – Part I
Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19.In part I of the episode, they discuss about the controversy surrounding the use of non-steroidal anti-inflammatory drugs (NSAIDs) and angiotensin-converting enzyme (ACE) inhibitors during the coronavirus pandemic, as well as the risk of patients with hypertension and diabetes in the context of COVID-19.×
References:
1.
Fang L, et al. Lancet 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? (Source)
2.
Pharmaceutical Society of Singapore. COVID-19 Advice for the General Public. (Source)
3.
WHO. Coronavirus disease (COVID-19) advice for the public: Myth-busters. (Source)
4.
ESC Guidance for the Diagnosis and Management of CV disease during the COVID-19 Pandemic. April 2020. (Source)
5.
Singapore Cardiac Society, Heart Failure Society (Singapore) and Academy of Medicine Singapore – Chapter of Cardiology Joint Position Statement on COVID-19 and use of ARB/ACEi. (Source)
21 May 2020
Metabolic
Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen
SC-MY-00695
Who SAID we can't ACE prescribing in the setting of COVID-19? – Part II
Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19.In part II of the episode, they discuss about the current evidence available on the potential therapies for COVID-19. They also discuss about considerations surrounding the use of these agents in COVID-19 patients during hospitalization and post-discharged.
×
References:
1.
FDA. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. (Source)
2.
Sanders JM, et al. JAMA 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (Source)
3.
Guidicessi JR, et al. Mayo Clin Proc 2020. Guidance for navigating QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. (Source)
21 May 2020
Metabolic
Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen
SC-MY-00696
Who SAID we can't ACE prescribing in the setting of COVID-19? – Part III
Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19.In part III of the episode, they discuss about the safety of statins during the COVID-19 pandemic and our guests share their most important takeaways on the use of medications in the setting of COVID-19.
×
References:
1.
Sanders JM, et al. JAMA 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (Source)
2.
ESC Guidance for the Diagnosis and Management of CV disease during the COVID-19 Pandemic. April 2020. (Source)
3.
WHO. Coronavirus disease (COVID-19) advice for the public: Myth-busters. (Source)
4.
Guidicessi JR, et al. Mayo Clin Proc 2020. Guidance for navigating QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. (Source)
27 April 2020
Metabolic
Speaker: Professor Dr.Rohana Abdul Ghani
PC-MY-100949
Fast Tips on Management of Diabetes During Ramadan
Our host today, Head of Medical at Boehringer Ingelheim, Dr Azhar, will be talking with Prof. Dr Rohana, the consultant endocrinologist and deputy dean at the faculty of Medicine, Universiti Teknologi MARA, to share with us some Fast Tips on the management of diabetes during Ramadan. Prof Rohana will also share what options the healthcare providers and the patients have available to optimize diabetes care during this COVID19 Cardiovascular
23 June 2020
Cardiovascular
Speaker: Dr. Gary Lee
SC-MY-00724
Managing Atrial Fibrillation in Elderly Patients.
Atrial Fibrillation is one of the most common diseases in aging population. In this podcast, Dr. Gary Lee, a Consultant Cardiologist & Electrophysiologist will be sharing his experience on what are the important managements in this group of patients.17 April 2020
Cardiovascular
Speaker: Prof. Dr. Chee Kok Han
SC-MY-00636
Managing Anticoagulation in Atrial Fibrillation during the COVID-19 Pandemic
The corona virus has brought changes to the way patients are being managed. Does this situation also affect the way Atrial Fibrillation patients are managed? Find out in this podcast where Prof. Dr. Chee Kok Han, Senior Consultant Cardiologist and Professor at the University of Malaya shares on the management of anticoagulated atrial fibrillation patients amidst the coronavirus pandemic.